<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30765453</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1757-790X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Feb</Month>
              <Day>13</Day>
            </PubDate>
          </JournalIssue>
          <Title>BMJ case reports</Title>
          <ISOAbbreviation>BMJ Case Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Bilateral osteonecrosis of the hip in panhypopituitarism.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e227471</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/bcr-2018-227471</ELocationID>
        <Abstract>
          <AbstractText>Osteonecrosis, also known as avascular necrosis, is a condition that causes significant morbidity and loss of function. It is a common complication seen with supraphysiological steroid use. Early diagnosis is critical as it impacts prognosis. We report a 20-year-old man who developed bilateral osteonecrosis of the hip following 6 years of low-dose steroid replacement therapy for panhypopituitarism secondary to a transsphenoidal resection of a growth hormone-secreting pituitary macroadenoma. The patient presented with several weeks of right-sided hip pain and significant loss of function. X-ray and MRI showed bilateral osteonecrosis of the hips with the right side more severely affected than the left. He was initiated on analgesics and bisphosphonates and underwent right hip total arthroplasty followed 1 year later by left hip arthroplasty. Postsurgery, the patient is mobilising well and his pituitary hormones are well balanced. He continues on low-dose glucocorticoid replacement which will continue lifelong.</AbstractText>
          <CopyrightInformation>© BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Uppal</LastName>
            <ForeName>Jasmene</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Burbridge</LastName>
            <ForeName>Brent</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arnason</LastName>
            <ForeName>Terra</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-5793-7713</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>02</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>BMJ Case Rep</MedlineTA>
        <NlmUniqueID>101526291</NlmUniqueID>
        <ISSNLinking>1757-790X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000700">Analgesics</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004164">Diphosphonates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013256">Steroids</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C580003">Combined Pituitary Hormone Deficiency</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000700" MajorTopicYN="N">Analgesics</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019644" MajorTopicYN="N">Arthroplasty, Replacement, Hip</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004164" MajorTopicYN="N">Diphosphonates</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005271" MajorTopicYN="N">Femur Head Necrosis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007018" MajorTopicYN="N">Hypopituitarism</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010911" MajorTopicYN="N">Pituitary Neoplasms</DescriptorName>
          <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013256" MajorTopicYN="N">Steroids</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">drugs: endocrine system</Keyword>
        <Keyword MajorTopicYN="N">pituitary disorders</Keyword>
        <Keyword MajorTopicYN="N">unwanted effects / adverse reactions</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: None declared.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30765453</ArticleId>
        <ArticleId IdType="pmc">PMC6382027</ArticleId>
        <ArticleId IdType="doi">10.1136/bcr-2018-227471</ArticleId>
        <ArticleId IdType="pii">12/2/bcr-2018-227471</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Kerachian MA, Séguin C, Harvey EJ. 
Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J Steroid Biochem Mol Biol
2009;114(3-5):121–8. 10.1016/j.jsbmb.2009.02.007
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jsbmb.2009.02.007</ArticleId>
            <ArticleId IdType="pmc">PMC7126235</ArticleId>
            <ArticleId IdType="pubmed">19429441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pazderska A, Crowther S, Govender P, et al. . 
Spontaneous resolution of avascular necrosis of femoral heads following cure of Cushing’s syndrome. Endocrinol Diabetes Metab Case Rep
2016;2016
10.1530/EDM-16-0015
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EDM-16-0015</ArticleId>
            <ArticleId IdType="pmc">PMC4870498</ArticleId>
            <ArticleId IdType="pubmed">27252864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cheng EY, Thongtrangan I, Laorr A, et al. . 
Spontaneous resolution of osteonecrosis of the femoral head. J Bone Joint Surg Am
2004;86-A:2594–9. 10.2106/00004623-200412000-00002
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2106/00004623-200412000-00002</ArticleId>
            <ArticleId IdType="pubmed">15590841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hossain MR, Karandish S, Khanal R, et al. . 
Unilateral femoral head osteonecrosis caused by low-dose oral corticosteroid used for secondary adrenal insufficiency from idiopathic hypopituitarism. J Med Cases
2017;8:227–9. 10.14740/jmc2857w
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14740/jmc2857w</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chan KL, Mok CC. 
Glucocorticoid-induced avascular bone necrosis: diagnosis and management. Open Orthop J
2012;6:449–57. 10.2174/1874325001206010449
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1874325001206010449</ArticleId>
            <ArticleId IdType="pmc">PMC3480825</ArticleId>
            <ArticleId IdType="pubmed">23115605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moya-Angeler J, Gianakos AL, Villa JC, et al. . 
Current concepts on osteonecrosis of the femoral head. World J Orthop
2015;6:590–601. 10.5312/wjo.v6.i8.590
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5312/wjo.v6.i8.590</ArticleId>
            <ArticleId IdType="pmc">PMC4573503</ArticleId>
            <ArticleId IdType="pubmed">26396935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jawad MU, Haleem AA, Scully SP. 
In brief: Ficat classification: avascular necrosis of the femoral head. Clin Orthop Relat Res
2012;470:2636–9. 10.1007/s11999-012-2416-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11999-012-2416-2</ArticleId>
            <ArticleId IdType="pmc">PMC3830078</ArticleId>
            <ArticleId IdType="pubmed">22760600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Weinstein RS.
Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am
2012;41:595–611. 10.1016/j.ecl.2012.04.004
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ecl.2012.04.004</ArticleId>
            <ArticleId IdType="pmc">PMC3417039</ArticleId>
            <ArticleId IdType="pubmed">22877431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fraser LA, Adachi JD. 
Glucocorticoid-induced osteoporosis: treatment update and review. Ther Adv Musculoskelet Dis
2009;1:71–85. 10.1177/1759720X09343729
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1759720X09343729</ArticleId>
            <ArticleId IdType="pmc">PMC3383483</ArticleId>
            <ArticleId IdType="pubmed">22870429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ibáñez D, Martín MD, Rubio RÁ, et al. . 
[Multifocal osteonecrosis in long-term corticoid treatment secondary to panhypopituitarism: a case report]. Endocrinol Nutr
2013;60:416–8. 10.1016/j.endonu.2012.07.011
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.endonu.2012.07.011</ArticleId>
            <ArticleId IdType="pubmed">23108054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dharmshaktu P, Aggarwal A, Dutta D, et al. . 
Bilateral femoral head avascular necrosis with a very low dose of oral corticosteroid used for panhypopituitarism. BMJ Case Rep
2016;2016:bcr2015212803
10.1136/bcr-2015-212803
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bcr-2015-212803</ArticleId>
            <ArticleId IdType="pmc">PMC4716313</ArticleId>
            <ArticleId IdType="pubmed">26762348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Powell C, Chang C, Naguwa SM, et al. . 
Steroid induced osteonecrosis: An analysis of steroid dosing risk. Autoimmun Rev
2010;9:721–43. 10.1016/j.autrev.2010.06.007
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2010.06.007</ArticleId>
            <ArticleId IdType="pmc">PMC7105235</ArticleId>
            <ArticleId IdType="pubmed">20621176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Felson DT, Anderson JJ. 
Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet
1987;1:902–6. 10.1016/S0140-6736(87)92870-4
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(87)92870-4</ArticleId>
            <ArticleId IdType="pubmed">2882300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dilisio MF, short-term Ofollowing. 
low-dose oral corticosteroids: a population-based study of 24 million patients. Orthopedics
2014;37:e631–e636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24992058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Aaron RK, Voisinet A, Racine J, et al. . 
Corticosteroid-associated avascular necrosis: dose relationships and early diagnosis. Ann N Y Acad Sci
2011;1240:38–46. 10.1111/j.1749-6632.2011.06218.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.2011.06218.x</ArticleId>
            <ArticleId IdType="pubmed">22172038</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
